How Omomyc Targets Myc for Cancer Therapy
Author Information
Author(s): Savino Mauro, Annibali Daniela, Carucci Nicoletta, Favuzzi Emilia, Cole Michael D., Evan Gerard I., Soucek Laura, Nasi Sergio
Primary Institution: Consiglio Nazionale delle Ricerche - Istituto di Biologia e Patologia Molecolari (CNR – IBPM), Dipartimento di Biologia e Biotecnologie, Università Sapienza, Roma, Italia
Hypothesis
Can the Myc inhibitor Omomyc provide insights into targeting Myc for cancer therapy?
Conclusion
Omomyc selectively alters Myc's function, promoting tumor suppression while inhibiting its oncogenic activity.
Supporting Evidence
- Omomyc demonstrated therapeutic efficacy in transgenic mouse cancer models.
- Omomyc selectively targets Myc protein interactions, reshaping the Myc transcriptome.
- Omomyc prevents Myc from activating certain genes while allowing repression of others.
- Omomyc alters epigenetic marks associated with Myc activity.
Takeaway
Omomyc is like a special tool that helps stop a bad guy called Myc from making cancer grow, while still letting some good things happen.
Methodology
The study involved experiments on transgenic mouse cancer models and various assays to analyze Myc interactions and gene expression.
Limitations
The study primarily focuses on in vitro and animal models, which may not fully replicate human responses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website